The Food and Drug Administration (FDA) has approved Arcalyst® (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin (IL)-1, a key cytokine that mediates the pathophysiology of many inflammatory processes, and has been implicated as a causative factor in pericarditis. The approval was based on data from the phase 3 RHAPSODY trial (ClinicalTrials.gov: NCT03737110).

The double-blind, randomized withdrawal study compared the efficacy and safety of rilonacept to placebo in 61 actively symptomatic recurrent pericarditis patients who were failing standard of care treatment, including nonsteroidal anti-inflammatory drugs, colchicine, or corticosteroids, and who achieved and maintained clinical response on rilonacept monotherapy during the run-in period. Results showed that treatment with rilonacept reduced the risk of recurrent pericarditis events by 96% compared with placebo (hazard ratio [HR] 0.04; P <.0001).

Additionally, patients who received rilonacept experienced no or minimal pericarditis pain for 92% of trial days compared with 40% of trial days for placebo recipients (P <.0001). The most common adverse events reported were injection site reactions and upper respiratory tract infections.


Continue Reading

“Data have shown that recurrent pericarditis stems from an underlying autoinflammatory pathophysiology mediated by IL-1α and IL-1β,” said Allan Klein, MD, of Cleveland Clinic, co-principal investigator of RHAPSODY and compensated member of a 2019 Kiniksa scientific advisory committee. “This approval supports the concept of a targeted immunomodulation therapeutic strategy as a paradigm shift in the management of patients with this devastating disease.”

Arcalyst is supplied as 220mg of lyophilized powder in a single-dose vial for reconstitution. A patient assistance program called Kiniksa One Connect™ has also been made available to support patients receiving Arcalyst.

Reference

Kiniksa announces FDA approval of ARCALYST ® (rilonacept) for recurrent pericarditis. [press release]. Hamilton, Bermuda: Kiniksa Pharmaceuticals; March 18, 2021.